Capabilities of Next-Generation Patch Pump: Improved Precision, Instant Occlusion Detection, and Dual-Hormone Therapy

Area of Science:

• Biomedical Engineering
• Drug Delivery Systems
• Diabetes Technology

Background:

• Current insulin pumps (continuous subcutaneous insulin infusion - CSII) offer improved glycemic control but are limited by size, cost, and intrusiveness.
• Limitations of existing insulin delivery devices necessitate innovation in wearable technology for enhanced patient convenience and adherence.

Purpose of the Study:

• To introduce a novel wearable patch pump technology developed by SFC Fluidics.
• To highlight the advantages of the electro-chemiosmotic (ECO) microfluidic pumping technology for insulin delivery.
• To present the key features and potential benefits of the new patch pump design for diabetes management.

Main Methods:

• Development of a wearable patch pump utilizing patented electro-chemiosmotic (ECO) microfluidic pumping technology.
• Incorporation of a nonmechanical pumping engine designed for small size, cost-effectiveness, and precision in delivering small drug volumes.
• Integration of safety features including latching safety valves and an instantaneous occlusion sensor.

Main Results:

• The ECO microfluidic technology enables accurate and precise delivery of small insulin doses, including concentrated formulations.
• The pump engine is designed for inexpensive manufacturing using injection molded parts, suitable for disposable or semi-disposable formats.
• The system includes advanced safety mechanisms to prevent accidental overdosing and detect delivery failures promptly.

Conclusions:

• SFC Fluidics' patch pump, based on ECO technology, offers a discreet, reliable, and potentially more affordable alternative for continuous subcutaneous insulin infusion (CSII) therapy.
• The technology facilitates precise drug delivery and incorporates safety features to enhance user confidence and therapeutic outcomes.
• This innovation has the potential to increase the accessibility and adoption of insulin pump therapy for individuals with diabetes.